The global tadalafil market is expected to rise at a considerable CAGR during the forecast period (2024-2031). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in March 2019, Dr. Reddy’s Laboratories announced the launch of  tadalafil tablets in the US market. The authorised product is a therapeutically equivalent generic form of Cialis (tadalafil) tablets. Dr. Reddy's Tadalafil pills are available in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg, each in a 30-count container size. Further, in February 2019, Cipla's Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg received final approval from the US Food and Drug Administration (US FDA). Cipla's Tadalafil Tablets 20mg are an AB-rated generic drug similar to Eli Lilly and Co.'s Adcirca. It's a phosphodiesterase 5 (PDE5) inhibitor intended to help persons with pulmonary arterial hypertension (PAH) exercise more effectively (WHO Group 1).

Get Free Sample link @ https://www.omrglobal.com/request-sample/tadalafil-market

Besides, in March 2019, after getting final approval from the US FDA to market the medication in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg, Zydus Cadila announced the Day 1 launch of Tadalafil Tablets USP (US RLD Cialis Tablets). The drug, is manufactured at the group's plant in Moraiya, Ahmedabad, and is used to treat erectile dysfunction (impotence) and the symptoms of benign prostatic hypertrophy (enlarged prostate).

Full report of Tadalafil Market available @ https://www.omrglobal.com/industry-reports/tadalafil-market

Market Coverage

Segment Covered- 

o             By Type

o             By Application

Regions Covered-

o             North America

o             Europe

o             Asia-Pacific

o             Rest of the World

1.1.        Competitive Landscape- Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Co. Pvt. Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., and others.

Key questions addressed by the report

What is the market growth rate?
That segment and region dominate the market in the base year?
That segment and region will project the fastest growth in the market?
How does COVID-19 impact the market?

o             Deviation from the pre-COVID-19 forecast

o             Most affected region and segment

Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Tadalafil Market Report by Segment

By Type

Purity: 98%
Purity: above 98%

By Application

Erectile Dysfunction
Benign Prostatic Hyperplasia
Others

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.




For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/tadalafil-market





Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.